|
GB0402318D0
|
|
Transgenic animals for assessing drug metabolism and toxicity in man
|
|
GB0216343D0
|
|
Biologically active molecule
|
|
GB0216203D0
|
|
Mondulation of cytochrome P450 reductase activity
|
|
WO02056213A2
|
|
Interactive tool for knowledge-based support of planning under uncertainty
|
|
US2002114813A1
|
|
Compounds
|
|
AU2378402A
|
|
Imaging, diagnosis and treatment of disease
|
|
WO0220786A2
|
|
Kinase d interacting protein
|
|
GB0115673D0
|
|
Cancer
|
|
AU5653001A
|
|
Drug screening systems and assays
|
|
GB0105063D0
|
|
Polypeptides
|
|
GB0101124D0
|
|
DNA Element and Associated Protein
|
|
US7060450B1
|
|
Screening assays for agonists and antagonists of the hedgehog signaling pathway
|
|
CA2374678A1
|
|
Diagnosis, prognosis and treatment of cancer related to the barx2 gene
|
|
GB0012179D0
|
|
Assays and drug screening systems
|
|
GB0007989D0
|
|
Methods
|
|
GB0005466D0
|
|
Cancer
|
|
AU1876900A
|
|
Cancer related to human chromosome 16q tumor suppressor gene
|
|
GB9921242D0
|
|
Cancer vaccine and diagnosis
|
|
GB9920000D0
|
|
Polypeptides
|
|
EP1102791A1
|
|
Modified green fluorescent protein
|
